[Federal Register: April 14, 2003 (Volume 68, Number 71)]
[Page 17960]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]



Food and Drug Administration

Vaccines and Related Biological Products Advisory Committee; 
Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Vaccines and Related Biological Products 
Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on May 8, 2003, from 1:30 
p.m. to 4 p.m.
    Location: Food and Drug Administration, 29 Lincoln Dr., bldg. 29B, 
conference room A, Bethesda, MD. This meeting will be held by a 
telephone conference call. The public is welcome to attend the open 
session of the meeting at the specified location.
    Contact Person: Jody G. Sachs or Denise H. Royster, Food and Drug 
Administration, Center for Biologics Evaluation and Research (HFM-71), 
301 827-0314, or FDA Advisory Committee Information Line, 1-800-741-
8138 (301-443-0572 in the Washington, DC area), code 12391. Please call 
the Information Line for up-to-date information on this meeting.
    Agenda: The committee will review and discuss the intramural 
research programs of the Laboratory of Mycobacterial Diseases & 
Cellular Immunology and the Laboratory of Method Development, in the 
Office of Vaccines Research and Review.
    Procedure: On May 8, 2003, from 1:30 p.m. to 3:30 p.m., the meeting 
is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person by 
April 25, 2003. Oral presentations from the public will be scheduled 
between approximately 2:30 p.m. and 3:30 p.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before April 25, 2003, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Closed Committee Deliberations: On May 8, 2003, from 3:30 p.m. to 4 
p.m., the meeting will be closed to permit discussion where disclosure 
would constitute a clearly unwarranted invasion of personal privacy (5 
U.S.C. 552b(c)(6)). The meeting will be closed to discuss personal 
information concerning individuals associated with the intramural 
laboratory research programs.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Jody G. Sachs or 
Denise H. Royster at least 7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: April 7, 2003.
Linda Arey Skladany,
Associate Commissioner for External Relations.
[FR Doc. 03-9030 Filed 4-11-03; 8:45 am]